Stevanato Group S.p.A. (STVN)
$
21.3
+0.48 (2.25%)
Key metrics
Financial statements
Free cash flow per share
0.0528
Market cap
4.9 Billion
Price to sales ratio
4.2261
Debt to equity
0.3155
Current ratio
1.8918
Income quality
1.9612
Average inventory
274.4 Million
ROE
0.0995
Technology
Technology – consumer electronics
Largecap
With a market cap of 121,78 bil stock is ranked 1
Low risk
ISS score of this stock is ranked 1
Company description
Profile
Stevanato Group S.p.A. is actively involved in the design, production, and distribution of integrated solutions tailored for the pharmaceutical and healthcare sectors. The company has reported an income before tax of $160,288,000.00 showcasing its pre-tax profitability, which reflects the efficacy of its operations. In addition to its core business activities, the net total of other income and expenses is -$854,000.00 highlighting the financial outcomes of non-core activities. Furthermore, the company incurred an interest expense of $6,864,000.00 which underscores its debt servicing obligations. Operationally, Stevanato Group S.p.A. reported selling, general, and administrative expenses of $118,600,000.00 indicating its overhead costs associated with daily operations. The EBITDA ratio is $0.22 providing insight into the company's operational efficiency and profitability. In terms of its market presence, the stock is considered affordable at $26.80 making it suitable for budget-conscious investors. The stock has an average trading volume of 327,938.00 indicating moderate liquidity, which can be beneficial for potential buyers. With a mid-range market capitalization of $5,813,762,308.00 the company is recognized as a steady performer in the market. Stevanato Group S.p.A. is a key player in the Medical - Instruments & Supplies industry, contributing significantly to the overall market landscape and reinforcing its relevance in the field. Additionally, it belongs to the Healthcare sector, where it drives innovation and growth through its diverse range of products and services.
Is Stevanato Group S.p.A. (STVN) a good investment?
Investing in Stevanato Group S.p.A. (STVN) depends on multiple factors, including revenue growth, profit margins, debt-to-equity ratio, earnings per share, and return on equity. Analysts have rated it as B-, with a Bearish outlook. Always conduct your own research before investing.
What is Stevanato Group S.p.A. (STVN)'s stock forecast?
Analysts predict Stevanato Group S.p.A. stock to fluctuate between $17.81 (low) and $28 (high) in the next 365 days, reflecting market expectations and potential volatility.
What is Stevanato Group S.p.A.'s market capitalization?
As of 2025-12-15, Stevanato Group S.p.A.'s market cap is $5,813,762,308, based on 272,946,597 outstanding shares.
How does Stevanato Group S.p.A. compare to competitors like Meta Platforms, Inc. Class A Common Stock?
Compared to Meta Platforms, Inc. Class A Common Stock, Stevanato Group S.p.A. has a Lower Market-Cap, indicating a difference in performance.
Does Stevanato Group S.p.A. pay dividends?
Stevanato Group S.p.A. pays dividends. The current dividend yield is 0.26%, with a payout of $0.06 per share.
How can I buy Stevanato Group S.p.A. (STVN) stock?
To buy Stevanato Group S.p.A. (STVN) stock: Open a brokerage account (e.g., Robinhood, TD Ameritrade, E-Trade). Search for STVN. Place an order (Market, Limit, etc.).
What is the best time to invest in Stevanato Group S.p.A.?
The best time to invest depends on market trends and technical indicators, which show a Bearish trend based on economic conditions and company performance.
How did Stevanato Group S.p.A. perform in the last earnings report?
Revenue: $1,104,036,000 | EPS: $0.43 | Growth: -21.82%.
Where can I find Stevanato Group S.p.A.'s investor relations reports?
Visit https://www.stevanatogroup.com/investor-relations for detailed financial reports.
Where can I find historical stock prices for Stevanato Group S.p.A.?
You can explore historical data from here
What is the all-time high and low for Stevanato Group S.p.A. stock?
All-time high: $36.30 (2023-08-09) | All-time low: $13.36 (2022-05-10).
What are the key trends affecting Stevanato Group S.p.A. stock?
Key trends include market demand, economic conditions, interest rates, and industry competition, which influence the stock's performance.
News
seekingalpha.com
Stevanato Group S.p.A. ( STVN ) Q3 2025 Earnings Call November 6, 2025 8:30 AM EST Company Participants Lisa Miles - Chief Communications & Investor Relations Officer Franco Stevanato - CEO & Executive Chairman Marco Dal Lago - Chief Financial Officer Conference Call Participants Lawrence Solow - CJS Securities, Inc. Matthew Larew - William Blair & Company L.L.C.
zacks.com
Stevanato Group (STVN) came out with quarterly earnings of $0.16 per share, beating the Zacks Consensus Estimate of $0.14 per share. This compares to earnings of $0.13 per share a year ago.
businesswire.com
PIOMBINO DESE, Italy--(BUSINESS WIRE)--Stevanato Group S.p.A. (NYSE: STVN), a leading global provider of drug containment, drug delivery, and diagnostic solutions to the pharmaceutical, biotechnology, and life sciences industries, today announced its financial results for the third quarter of 2025. Third Quarter 2025 Highlights (comparisons to prior-year period) Revenue increased 9% (11% on a constant currency basis) to €303.2 million. High-value solutions represented a record 49% of total reve.
businesswire.com
PIOMBINO DESE, Italy--(BUSINESS WIRE)--Stevanato Group S.p.A. (NYSE: STVN), a leading global provider of drug containment, drug delivery, and diagnostic solutions to the pharmaceutical, biotechnology, and life sciences industries, today announced that it will participate in two upcoming investor conferences. Monday, November 17, 2025, at 8:40 a.m. ET - The 7th Annual Wolfe Research Healthcare Conference in New York City Wednesday, November 19, 2025, at 11:00 a.m. GMT - The Jefferies Global Heal.
businesswire.com
PIOMBINO DESE, Italy--(BUSINESS WIRE)--Stevanato Group S.p.A. (NYSE: STVN), a leading global provider of drug containment, drug delivery, and diagnostic solutions to the pharmaceutical, biotechnology, and life sciences industries, announced today that it will issue financial results for the third quarter of 2025 on Thursday, November 6, 2025, at 6:30 a.m. (ET). Conference call and webcast: The Company will host a conference call and webcast at 8:30 a.m. (ET) on Thursday, November 6, 2025, to di.
seekingalpha.com
Stevanato Group S.p.A. (NYSE:STVN ) Bank of America Global Healthcare Conference 2025 September 24, 2025 5:45 AM EDT Company Participants Marco Dal Lago - Chief Financial Officer Conference Call Participants Michael Ryskin - BofA Securities, Research Division Presentation Michael Ryskin BofA Securities, Research Division I'm on the Bank of America Life Science Tools and Diagnostics team based out of New York.
zacks.com
Stevanato (STVN) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
businesswire.com
PIOMBINO DESE, Italy--(BUSINESS WIRE)--Stevanato Group S.p.A. (NYSE: STVN), a leading global provider of drug containment, drug delivery, and diagnostic solutions to the pharmaceutical, biotechnology, and life sciences industries, today announced that it will participate in two upcoming investor conferences. Tuesday, September 9, 2025, at 7:45 a.m. ET - The 23rd Annual Morgan Stanley Global Healthcare Conference in New York City Wednesday, September 24, 2025, at 10:45 a.m. BST - The Bank of Ame.
zacks.com
Stevanato Group (STVN) came out with quarterly earnings of $0.12 per share, beating the Zacks Consensus Estimate of $0.11 per share. This compares to earnings of $0.1 per share a year ago.
businesswire.com
PIOMBINO DESE, Italy--(BUSINESS WIRE)--Stevanato Group S.p.A. (NYSE: STVN), a leading global provider of drug containment, drug delivery, and diagnostic solutions to the pharmaceutical, biotechnology, and life sciences industries, today announced its financial results for the second quarter of 2025. Second Quarter 2025 Highlights (comparisons to prior-year period) Revenue increased 8% to €280.0 million, and high-value solutions represented 42% of total revenue. Gross profit margin increased 210.
See all news
